Breaking Down Guilin Sanjin Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Investors peering into Guilin Sanjin Pharmaceutical (002275.SZ) will find a compact but revealing financial snapshot: operating revenue of CNY 1.462 billion in the first three quarters of 2025, down 7.14% year‑over‑year from 2024 while full‑year 2024 revenue was CNY 2.19 billion (a 1.03% rise), net profit attributable to shareholders of CNY 385 million through Q3 2025 (up 0.35% YoY), and robust profitability metrics including a 73.41% gross margin, a 29.39% operating margin and a 25.12% net margin; balance sheet and liquidity indicators show net cash with CNY 1.05 billion in cash versus CNY 475.6 million debt, a current ratio of 2.5 and cash ratio of 1.2, while valuation and investor returns include an approximate market cap of CNY 8.66 billion, P/E of 16.33, P/B of 1.2, a dividend yield of 3.78% and a P/S around 4.1 - set against conservative leverage (gearing 24.53%), high cash conversion (operating cash flow CNY 588.3 million), a workforce of 2,567 with revenue per employee of CNY 848,450, and strategic growth ambitions like CNY 200 million for solar projects and a target of 40% international sales by 2025 amid regulatory and competitive risks in the TCM sector, all of which frame the deeper analysis ahead.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) - Revenue Analysis

Key top-line figures and structural drivers for Guilin Sanjin's revenue profile through recent periods and per-employee productivity.

• Operating revenue (Jan-Sep 2025): CNY 1.462 billion (down 7.14% vs. same period 2024).
• Annual operating revenue (2024): CNY 2.19 billion (up 1.03% vs. 2023).
• Revenue per employee: CNY 848,450 based on 2,567 employees.
• Market capitalization: ~CNY 8.66 billion; price-to-sales (P/S) ratio: 3.98.
• 5-year revenue CAGR: ≈3.2%.
• Primary revenue drivers: established consumer healthcare brands such as Guilin watermelon frost and throat lozenges.

• Revenue composition: a large share derives from flagship OTC consumer products (Guilin watermelon frost, throat lozenges), benefiting from brand recognition and retail penetration.
• Implications of recent Q1-Q3 2025 decline: seasonal/product-cycle effects, competitive pressure in OTC segment, or distribution adjustments may be contributing factors to monitor.
• Valuation context: P/S ~3.98 implies market pricing that reflects expectations for modest growth and brand-driven margin resilience relative to peers.

Further company background and commercial model: Guilin Sanjin Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) - Profitability Metrics

• Net profit attributable to shareholders (Q1-Q3 2025): CNY 385 million (+0.35% YoY)
• Gross profit margin: 73.41% - indicating strong product-level profitability and pricing power
• Operating profit margin: 29.39% - reflecting effective cost control and operating leverage
• EBITDA: CNY 767.86 million; EBITDA margin: 35.00% - strong cash-generation proxy
• Return on equity (ROE): 16.71% - above-average shareholder returns
• Net profit margin: 25.12% - demonstrates healthy bottom-line conversion from revenue

• High gross margin (73.41%) implies either premium pricing, low direct costs or a favorable sales mix toward higher-margin formulations.
• EBITDA margin (35.00%) and operating margin (29.39%) together point to scalable operations with meaningful cash flow available for reinvestment, deleveraging or shareholder returns.
• ROE of 16.71% signals efficient use of equity capital to generate profit, supporting potential for sustained shareholder value if capital structure and asset returns persist.
• The modest YoY net profit growth (+0.35%) despite strong margins suggests possible one-off items, investment, or market dynamics affecting top-line growth-investors should review revenue trends and expense drivers in quarterly disclosures.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) - Debt vs. Equity Structure

• Total debt: CNY 475.6 million.
• Cash and cash equivalents: CNY 1,050.0 million.
• Net cash position: CNY 574.4 million (cash minus debt).
• Gearing ratio: 24.53% - indicative of conservative leverage.
• Debt-to-equity ratio: ~0.56 - balanced capital structure.
• Operating cash flow: CNY 588.3 million - significantly above reported net income.
• Capital expenditures: CNY 82.2 million - moderate reinvestment level.
• Beta: 0.416 - defensive equity volatility relative to the market.

• Cash profile: With CNY 1.05 billion on hand against CNY 475.6 million debt, the company can cover obligations comfortably and fund near-term projects without needing external financing.
• Cash flow dynamics: Operating cash flow of CNY 588.3 million exceeds CapEx by roughly 7.15x, leaving ample free cash for dividends, buybacks, M&A, or debt reduction.
• Leverage implications: A 24.53% gearing and 0.56 debt-to-equity ratio reduce financial risk and support flexibility in capital allocation during downturns.
• Investor fit: Beta of 0.416 aligns the stock with more risk-averse investors seeking defensive exposure within the pharmaceutical sector.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) Liquidity and Solvency

• Current ratio: 2.5 - indicates sufficient short-term assets to cover current liabilities.
• Quick ratio: 1.8 - strong liquidity excluding inventory.
• Cash ratio: 1.2 - ample cash to meet immediate obligations.
• Interest coverage ratio: 10 - comfortably covers interest expenses from operating profit.
• Operating cash flow ratio: 1.5 - efficient conversion of sales/profits into cash.
• Net working capital: CNY 500 million - operational buffer for day-to-day needs.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) - Valuation Analysis

• Relative valuation: P/E of 16.33 sits close to many domestically focused mid-cap pharmaceutical peers - not inexpensive but not stretched.
• Balance-sheet premium: P/B at 1.2 signals modest investor willingness to pay above net asset value, consistent with stable earnings or intangible asset value.
• Revenue multiple: P/S of 4.11 implies investors value each yuan of revenue at ~CNY 4.11, useful when comparing top-line growth prospects across peers.
• Income component: 3.78% dividend yield enhances total return potential, particularly for yield-seeking portfolios in a low-rate environment.
• Volatility context: 52-week band (CNY 12.90-17.38) suggests limited downside relative to some small-cap pharma names but still room for price movement.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) - Risk Factors

• Regulatory Environment: China's pharmaceutical regulations and drug approval pathways continue to evolve, with increased scrutiny on quality, traceability and clinical evidence. Changes can delay product launches, require additional compliance spend, or restrict sales of certain formulations.
• Market Competition: The TCM market is fragmented but intensely competitive, with national players, regional branded manufacturers and generic producers vying on price and distribution reach.
• Portfolio Concentration: A high reliance on TCM product lines concentrates revenue risk, limiting buffers against downturns in any single therapeutic category or demographic shift away from traditional therapies.
• Raw Material Price Volatility: Many TCM formulations depend on botanical and animal-derived materials whose prices can swing due to weather, harvest yields, or supply-chain disruptions.
• Limited International Diversification: Heavy dependence on China's domestic market increases exposure to local policy shifts, reimbursement changes and consumer sentiment trends.
• Changing Consumer Preferences: Younger cohorts show growing interest in modern pharmaceuticals, nutraceuticals and wellness products, which could reduce demand for some traditional formulations over time.

• Financial sensitivity: Given typical margins for established TCM manufacturers, a simultaneous regulatory tightening and raw-material cost spike could compress net margins by a cumulative 6-20% in the near term, stressing cash flows and potentially reducing free cash flow available for R&D or expansion.
• Balance sheet considerations: Investors should monitor short-term liquidity metrics (current ratio, quick ratio) and debt maturities - companies with higher leverage face greater vulnerability to revenue shocks or increased compliance costs.
• Mitigants adopted by peers: vertical integration of raw-material sourcing, diversification into OTC/healthcare products, expansion of online sales channels, and selective internationalization to reduce single-market exposure.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) - Growth Opportunities

• Carbon neutrality target: achieve net-zero emissions by 2030, with an interim goal of 30% reduction in water usage by 2025.
• Renewable energy investment: CNY 200 million earmarked for solar energy projects to lower energy costs and reduce direct emissions.
• International sales expansion: target to increase exports and overseas revenue to 40% of total revenue by 2025.
• Global partnerships: active collaboration with 10 global health organizations to accelerate market access and credibility overseas.
• Product pipeline: development and commercialization of new, patented formulations including Naomaitai capsules.
• Regulatory alignment: focus on standardized TCM preparations to meet evolving GMP and international regulatory requirements.

• CapEx and cash flow: CNY 200 million solar allocation will be a near-term capital outlay; potential payback depends on energy cost savings and available subsidies.
• Revenue mix shift: reaching 40% international revenue will require scaling of sales, distribution and compliance functions; FX exposure and pricing strategies will matter.
• R&D and IP: patented products such as Naomaitai could lift gross margins if successfully protected and commercialized in higher-price markets.
• Sustainability KPIs: water-use reduction and carbon targets can reduce regulatory and reputational risk while potentially unlocking green financing options.

• Execution risk: meeting 40% international revenue and delivering patented product sales depends on successful market entry and distribution scaling.
• Capital allocation trade-offs: CNY 200 million in solar projects may constrain other investments if not financed externally.
• Regulatory risk: faster regulatory tightening on TCM or differing international standards could raise compliance costs and delay launches.
• Market acceptance: standardized TCM and patented products must overcome perception and reimbursement hurdles in target markets.